Studies on Novel Bacterial Translocase I Inhibitors, A-500359s

V. Enhanced Production of Capuramycin and A-500359 A in *Streptomyces griseus* SANK 60196

Yasunori Muramatsu, Masatoshi Arai, Yoshiharu Sakaida, Yasuyuki Takamatsu, Shunichi Miyakoshi, Masatoshi Inukai

Received: June 21, 2006 / Accepted: September 12, 2006

© Japan Antibiotics Research Association

Abstract *Streptomyces griseus* SANK 60196 produces the novel nucleoside antibiotics A-500359 A, C, D and capuramycin. Enhanced production of capuramycin and A-500359 A was achieved through a number of medium modifications and a series of single colony isolations. The addition of maltose instead of glucose as the carbon source in a primary medium resulted in a 20-fold increase in the productivity of capuramycin. Furthermore, the addition of cobalt chloride (CoCl₂) and yeast extract to the medium containing maltose drastically altered the production ratio of A-500359 A to capuramycin. Thus, the yield of A-500359 A increased up to 600 µg/ml in an optimal medium, while the yield in the primary medium was 1 µg/ml.

Keywords capuramycin, translocase I, A-500359 A

Introduction

Since bacterial phospho-*N*-acetylmuramyl-pentapeptide-translocase (translocase I), which catalyzes the first step in the lipid cycle of peptidoglycan biosynthesis, is essential and specific for bacteria, it is thought to be an attractive target for the development of antimicrobial agents. In the course of our screening for bacterial translocase I

inhibitors, we found inhibitory activity in the cultured broth of *Streptomyces griseus* SANK 60196 and isolated the novel capuramycin derivatives A-500359s [1]. One of the compounds, A-500359 A, inhibited the enzyme with an IC₅₀ value of 0.017 µM and showed potent antimicrobial activity against *Mycobacterium smegmatis* ATCC 607 with an MIC value of 6.25 µg/ml [2].

However, the productivity of capuramycin and A-500359 A in the strain needed to be improved in order to obtain sufficient quantities of these compounds as substrates for chemical modification sources. In this paper, we describe the enhanced production of capuramycin and A-500359 A in *S. griseus* SANK 60196 achieved through modifications to fermentation media and a series of single colony isolations.

Materials and Methods

Materials

Medium 1 (PM-1) composed of glucose 2%, soluble starch 1%, pressed yeast 0.9%, Polypepton (Nihon Seiyaku) 0.5%, meat extract (Kyokuto) 0.5%, NaCl 0.5%, CaCO₃ 0.3% and CB-442 (NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization) was used as a primary medium. We also used Basal medium 1 (BM-1) in which any carbon sources were eliminated from the PM-1 medium. Basal medium 2 (BM-2) consisted of maltose 3%, NaCl 0.5%, CaCO₃ 0.3% and CB-442 (NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization). Primary medium 2 (PM-2) was a modified version in which 0.5% Polypepton and 0.5% meat extract

Y. Muramatsu (Corresponding author), **M. Arai**, **Y. Sakaida**, **Y. Takamatsu**, **S. Miyakoshi**, **M. Inukai**: Lead Discovery Research Laboratories, Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, E-mail: yasuno@sankyo.co.jp

were added to BM-2. The optimized medium 1 (OM-1), composed of maltose 3%, Polypepton 0.5%, meat extract 0.5%, yeast extract (Difco) 0.5%, NaCl 0.5%, CaCO_3 0.3%, $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ 0.001% and CB-442 (NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization) was used for jar fermentation.

Isolation of Spontaneous Variations

After 7 to 10 days of growth on ISP#2 medium (Difco) at 23°C, spores of *S. griseus* SANK 60196 were inoculated onto plates with the same composition. After a 14-day cultivation at 23°C, at least 50 colonies were picked up and transferred to a solid medium.

Flask Fermentation

A culture of *S. griseus* SANK 60196 and the isolated single colonies grown on ISP#2 medium for 7 to 10 days were used to inoculate 500-ml Erlenmeyer flasks containing 80 ml of PM-1. Four to five days after inoculation, 2.4 ml of the cultured medium was transferred to 500-ml Erlenmeyer flasks containing the same fresh medium and incubated for 7 to 9 days at 23°C on a rotary shaker (210 rpm).

Jar Fermentation

Two loopfuls of spores from a culture of the strain SANK 60196 were inoculated into a 2-liter Erlenmeyer flask containing 500 ml of PM-2 medium. The inoculated flask was incubated on a rotary shaker (210 rpm) at 23°C for 5 days. Then a 300-ml aliquot of the culture was transferred into a 30-liter jar fermentor containing 15 liters of OM-1. Fermentation was carried out at 23°C for 8 days with an air-flow rate of 15 liters/minute and an agitation rate of 100 to 400 rpm.

Determination of Productivity

The yields of A-500359 A, C, D and capuramycin in each culture were analyzed by HPLC. The harvested broth was centrifuged (3,000 rpm, 10 minutes) and the resulting supernatant (5 ml) was adsorbed on a Seppak plus cartridge C18 (Waters). The cartridge was washed with 2 ml of water and eluted with 2 ml of 20% aqueous acetonitrile. The eluate was applied to an HPLC column (Senshu Pak ODS-H-2151, Senshu Scientific; mobile phase: acetonitrile - 0.04% aqueous trifluoroacetic acid [8:92]; flow rate: 1.0 ml/minute). A-500359 A and capuramycin were eluted at the retention times of 18.7 minutes and 8.1 minutes, respectively.

Results

Enhanced Production of Capuramycin

Although *S. griseus* SANK 60196 produced 5 µg/ml of capuramycin in PM-1, the medium in which we first detected the inhibitory activity, the productivity was insufficient for chemical derivatization. In order to improve the capuramycin production, we examined the effects of glucose, starch, sucrose, maltose, glycerol and lactose as carbon sources. Fig. 1A shows that maltose at 3% gave the best production levels, while the other carbon sources failed to improve the production.

The effects of various nitrogen sources were examined using BM-2, a modified medium that was free of any nitrogen sources and contained 3% maltose instead of glucose. As a result, the production of capuramycin in the medium containing meat extract 0.5% and Polypepton 0.5% reached 80 µg/ml, while a slight enhancement of productivity was observed using either [meat extract 1% alone], [meat extract 0.5% and pressed yeast 0.9%] or [Polypepton 0.5% and pressed yeast 0.9%] (Fig. 1B). No production of capuramycin was observed with the other nitrogen sources tested in the experiment. Furthermore, the improvement resulting from the addition of meat extract and Polypepton was cancelled out when the concentration of maltose was raised to 5% (data not shown).

Next, we investigated the effect of cultivation temperature. As the temperature increased, the growth rate and fragmentation of mycelium increased along with rising pH (data not shown). However, the best production of capuramycin was observed at the lowest temperature, 23°C (Fig. 2). No further enhancement of the production was observed below 23°C (data not shown).

The production of capuramycin reached 100 µg/ml using the medium (PM-2), consisting of maltose 3%, Polypepton 0.5%, meat extract 0.5%, NaCl 0.5%, CaCO_3 0.3% and CB-442 (NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization) at 23°C, whereas the strain produced 5 µg/ml of the compound in the primary medium (PM-1) at 28°C.

Single Colony Isolations

A series of single colony isolations was carried out in order to obtain stable clones for the production of capuramycin. One loopful of each colony obtained by the method described in Materials and Methods was cultured in 100-ml Erlenmeyer flasks, each containing 20 ml of PM-2 medium at 23°C for 3 days, and the resulting seed culture (2.4 ml) was transferred into 500-ml Erlenmeyer flasks, each containing 80 ml of the same medium. After 8 days cultivation at 23°C, the productivity of the capuramycin

Fig. 1 Effects of various carbon and nitrogen sources on capuramycin production. (A) Each carbon source shown below was added to BM-1. (B) Each nitrogen source (ME: meat extract, PY: pressed yeast, PP: Polypepton, WP: wheat protein, GM: gluten meal, SBM: soybean meal, PHM: pharmedia) was added to BM-2 containing 3% maltose as a carbon source.

Fig. 2 Effect of cultivation temperature on capuramycin production.

The strain was cultured in PM-1 at various temperatures for 6 to 8 days.

Fig. 3 Production of capuramycin by single colony isolation using strain 1M-3, which showed 247 µg/ml of productivity in the first isolation.

was determined by HPLC using the method described previously. Two strains showing a productivity of 200 $\mu\text{g/ml}$ or more were obtained in the first isolation. One strain named 1M-3, which showed 247 $\mu\text{g/ml}$ of productivity in the first isolation, was adopted for the second isolation as the parent strain. Ninety percent of the isolates from the second isolation produced over 200 $\mu\text{g/ml}$ of capuramycin.

The most efficacious isolate, designated as 2M-30, produced 319 $\mu\text{g/ml}$ of the compound in the second isolation experiment (Fig. 3).

Enhanced Production of A-500359 A

Improvement of the production of A-500359 A, the main starting material for derivatization, was needed, since

Fig. 4 Effects of various metal ions on the production of capuramycin and A-500359 A.

(A) Each metal ion shown below was added to primary medium-2 (PM-2) described in Materials and Methods. The addition of cobalt chloride drastically altered the production ratio of A-500359 A to capuramycin. (B) Various concentrations of cobalt chloride were added to PM-2 and incubated for 9 days at 23°C on a rotary shaker.

Fig. 5 Effect of cobalt chloride and yeast extract (YE) on the production of capuramycin and A-500359 A. Each source was added to the primary medium-2 (PM-2) and incubated for 9 days at 23°C on a rotary shaker.

A-500359 A was a minor component in the primary medium at the time we first discovered the inhibitory activity. A-500359 A has an extra methyl carbon at the 6''' position on the aminocaprolactam ring of capuramycin and transmethylation might participate in the biosynthesis of A-500359 A. It is known that methylcobalamin, a derivative of vitamin B₁₂, plays a role as a methyl donor in both mammals and bacteria [3, 4], so we investigated the effect of various metal ions including Co²⁺ in order to alter the productivity of A-500359 A. As we expected, the production ratio of A-500359 A to capuramycin changed remarkably when CoCl₂ was added to PM-2 medium, while no enhancement effect of A-500359 A production was observed with other ions (Fig. 4A). Next we examined the concentration of CoCl₂ (0.001%~0.01%), and found that 0.001% of CoCl₂ was sufficient to alter the production ratio (Fig. 4B).

Through various supplementation trials, we discovered that an addition of yeast extract enhanced A-500359 A production, and that a synergistic effect was observed when CoCl₂ and yeast extract were used together. (Fig. 5) Using the medium containing CoCl₂ 0.001% and yeast extract 1.0%, the production level of A-500359 A reached 600 µg/ml while the production in the primary medium (PM-1) at the very beginning of the study had been 1 µg/ml.

Based on the above investigations, we tried to obtain large amounts of A-500359 A by jar fermentation (Fig. 6). Production of A-500359 A and capuramycin reached

Fig. 6 Fermentative productivity of A-500359 A by *S. griseus* SANK60196 using optimized medium OM-1 in a 30-liter fermentor.

* PCV indicates packed cell volume.

583 µg/ml and 45 µg/ml, respectively, in the optimal medium-1 (OM-1) which contained both yeast extract 0.5% and CoCl₂ 0.001%.

Discussion

Capuramycin is a nucleoside antibiotic first reported by H. Yamaguchi *et al.* in 1986 [5]. According to the report, 0.2 g of capuramycin was obtained using 5 liters of medium composed of glycerol, meat extract, Polypepton and

NaCl. The productivity in the report was estimated to be 60~80 $\mu\text{g/ml}$, which was over ten-fold higher than the productivity at the time when we first started this study. Through medium modification using maltose, Polypepton and meat extract, the production of capuramycin could be improved up to 100 $\mu\text{g/ml}$. The desirable effect caused by the addition of meat extract and Polypepton was cancelled out when the concentration of maltose was raised to 5%. This might indicate that the productivity of capuramycin depends on nutrient-limited conditions that are determined by the concentrations of meat extract and Polypepton. Monitoring the culture conditions, we observed that the easily digested nutrients such as glucose were consumed at an early stage of the cultivation, accompanied by a rapid increase of pH, which caused lower productivity. A cultivation temperature of 23°C was found to be the most suitable for capuramycin production and exhibited a delayed increase of pH. These observations might indicate that relatively high productivity is achieved when the metabolic turnover of the strain is down regulated to avoid the rapid increase of pH.

When we examined the effect of metal ions added to PM-2 medium as a basal medium, only the addition of Co^{2+} was effective to alter the main product. The structure of A-500359 A was elucidated as 6'''-methyl derivative of capuramycin, as reported previously [1]. Therefore, a methyl transfer step or steps may be involved in the biosynthesis of A-500359 A. Since methylcobalamin, a derivative of vitamin B12, is known as a methyl donor in both mammals and bacteria [3, 4], and it needs Co^{2+} for its activity, it might play a role in the biosynthesis of A-500359 A in the producing strain. Furthermore, we discovered that the addition of yeast extract enhanced A-

500359 A production, and a synergistic effect was observed when CoCl_2 was added together with yeast extract. As yeast extract is known to be rich in vitamins, it might enhance the methyl transfer step(s) in the biosynthesis of A-500359 A via methylcobalamin system(s).

Improvement of the culture conditions resulted in high and selective production of A-500359 A. However, higher productivity may be achieved by further optimization along these lines.

References

1. Muramatsu Y, Muramatsu A, Ohnuki T, Ishii MM, Kizuka M, Enokita R, Tsutsumi S, Arai M, Ogawa Y, Suzuki T, Takatsu T, Inukai M. Studies on novel bacterial translocase I inhibitors, A-500359s. I. Taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359 A, C, D and G. *J Antibiot* 56: 243–252 (2003)
2. Muramatsu Y, Ishii MM, Inukai M. Studies on novel bacterial translocase I inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G. *J Antibiot* 56: 253–258 (2003)
3. Matthews RG. Cobalamin-dependent methyltransferases. *Acc Chem Res* 34: 681–689 (2001)
4. Pfohl-Leszkowicz A, Keith G, Dirheimer G. Effect of cobalamin derivatives on *in vitro* enzymatic DNA methylation: methylcobalamin can act as a methyl donor. *Biochemistry* 30: 8045–8051 (1991)
5. Yamaguchi H, Sato S, Yoshida S, Takada K, Itoh M, Seto H, Otake N. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. *J Antibiot* 39: 1047–1053 (1986)